• Indoco Remedies Board approved slump sale of its ophthalmic division to Sunways India for ₹110 crore consideration.
• The division contributed ₹47.79 crore (3.2%) to standalone revenue in FY25 and operates in 16 territories including India and Africa.
• Transaction is not a related party deal and is expected to complete in three months subject to conditions precedent.
• Rationale is to focus on core therapeutic areas as ophthalmic business represents non-core segment for the company.